A sesquiterpenelactone from Inula britannica induces anti-tumor effects dependent on Bcl-2 phosphorylation

Anticancer Research

Volumn 25, Issue 1 A, 2005, Pages 313-318

  Rafi, Mohamed M ^a   Bai, Nai Sheng ^a   Chi Tang Ho, ^a   Rosen, Robert T ^a   White, Eileen ^b,c   Perez, Denise ^b   Dipaola, Robert S ^c  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Anti tumor; Apoptotic proteins; Bcl 2; Bcl 2 phosphorylation; Sesquiterpenelactones; Taxol

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; O ACETYLBRITANNILACTONE; O,O DIACETYLBRITANNILACTONE; PACLITAXEL; PROTEIN BCL 2; PROTEIN P53; SESQUITERPENE LACTONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CELL CYCLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ISOLATION; FLOW CYTOMETRY; FLUORESCENCE; IMMUNOBLOTTING; INULA; INULA BRITANNICA; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; RAT; WESTERN BLOTTING;

ANIMALS; CELL CYCLE; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; FLOWERS; HUMANS; INULA; LACTONES; MUTAGENESIS, SITE-DIRECTED; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; SESQUITERPENES;

EID: 16344372465     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Greenlee RT, Murray T, Bolden S and Wingo PA: Cancer statistics, 2000. CA Cancer J Clin 50: 7-33, 2000.
2. Sullivan GF, Amenta PS, Villanueva JD, Alvarez CJ, Yang JM and Hait WN: The expression of drug resistance gene products during the progression of human prostate cancer. Clin Cancer Res 4: 1393-1403, 1998.
3. Reed JC: Double identity for proteins of the Bcl-2 family. Nature 387: 773-776, 1997.
4. Tsujimoto Y and Croce CM: Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 83: 5214-5218, 1986.
5. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM and Campbell ML: Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52: 6940-6944, 1992.
6. Tu SM, McConnell K, Marin MC, Campbell ML, Fernandez A, von Eschenbach AC and McDonnell TJ: Combination adriamycin and suramin induces apoptosis in bcl-2 expressing prostate carcinoma cells. Cancer Lett 93: 147-155, 1995.
7. Haldar S, Chintapalli J and Croce CM: Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 56: 1253-1255, 1996.
8. Haldar S, Jena N and Croce CM: Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA 92: 4507-4511, 1995.
9. Srivastava RK, Mi QS, Hardwick JM and Longo DL: Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. Proc Natl Acad Sci USA 96: 3775-3780, 1999.
10. Ling YH, Tornos C and Perez-Soler R: Phosphorylation of Bcl-2 is a marker of M phase events and not a determinant of apoptosis. J Biol Chem 273: 18984-18991, 1998.
11. Britten CD, Hilsenbeck SG, Eckhardt SG, Marty J, Mangold G, MacDonald JR, Rowinsky EK, Von Hoff DD and Weitman S: Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model. Cancer Res 59: 1049-1053, 1999.
12. Eckhardt SG, Baker SD, Britten CD, Hidalgo M, Siu L, Hammond LA, Villalona-Calero MA, Felton S, Drengler R, Kuhn JG, Clark GM, Smith SL, MacDonald JR, Smith C, Moczygemba J, Weitman S, Von Hoff DD and Rowinsky EK: Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies. J Clin Oncol 18: 4086-4097, 2000.
13. El-Gamal AA: Sesquiterpene lactones from Smyrnium olusatrum. Phytochemistry 57: 1197-1200, 2001.
14. Pesando D, Huitorel P, Dolcini V, Amade P and Girard JP: Caulerpenyne interferes with microtubule-dependent events during the first mitotic cycle of sea urchin eggs. Eur J Cell Biol 77: 19-261998.
15. Muller WE, Dogovic N, Zahn RK, Maidhof A, Diehl-Seifert B, Becker C, Sachsse W, Gasic MJ and Schroder HC: Inhibition of mitosis by avarol, a natural product isolated from the sponge Dysidea avara. Basic Appl Histochem 29: 321-330, 1985.
16. White SJ and Jacobs RS: Inhibition of cell division and of microtubule assembly by elatone, a halogenated sesquiterpene. Mol Pharmacol 20: 614-620, 1981.
17. Zhou B-N, Bai N-S, Long-Ze L and Cordella GA: Sesquiterpene lactones from Inula britannica. Phytochemistry 34: 249-252, 1993.
18. Park EJ and Kim J: Cytotoxic sesquiterpene lactones from Inula britannica. Planta Med 64: 752-754, 1998.
19. Whan Ran J, Gon Lee B, Kee Kim Y, Woo Yoon J, Kyoung Jin H, Hong S, Young Lee H, Ro Lee K and Woo Lee H: Ergolide, sesquiterpene lactone from Inula britannica, inhibits inducible nitric oxide synthase and cyclo-oxygenase-2 expression in RAW 264.7 macrophages through the inactivation of NF-kappaB. Br J Pharmacol 133: 503-512, 2001.
20. Gingrich JR, Tucker JA, Walther PJ, Day JW, Poulton SH and Webb KS: Establishment and characterization of a new human prostatic carcinoma cell line (DuPro-1). J Urol 146: 915-919, 1991.
21. Hammond LA, Hilsenbeck SG, Eckhardt SG, Marty J, Mangold G, MacDonald JR, Rowinsky EK, Von Hoff DD and Weitman S: Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV522 lung carcinoma xenograft model. Eur J Cancer 36: 2430-2436, 2000.
22. Patel NM, Nozaki S, Shortle NH, Bhat-Nakshatri P, Newton TR, Rice S, Gelfanov V, Boswell SH, Goulet RJ Jr, Sledge GW Jr and Nakshatri H: Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide. Oncogene 19: 4159-4169, 2000.
23. Ross JJ, Arnason JT and Birnboim HC: Low concentrations of the feverfew component parthenolide inhibit in vitro growth of tumor lines in a cytostatic fashion. Planta Med 65: 126-129, 1999.
24. Thomas A, Giesler T and White E: p53 mediates bcl-2 phosphorylation and apoptosis via activation of the Cdc42/JNK1 pathway. Oncogene 19: 5259-5269, 2000.
25. Rafi MM, Rosen RT, Vassil A, Ho CT, Zhang H, Ghai G, Lambert G and DiPaola RS: Modulation of bcl-2 and cytotoxicity by licochalcone-A, a novel estrogenic flavonoid. Anticancer Res 20: 2653-2658, 2000.
26. Rafi MM, Vastano BC, Zhu N, Ho CT, Ghai G, Rosen RT, Gallo MA and DiPaola RS: Novel polyphenol molecule isolated from licorice root (Glycnhiza glabra) induces apoptosis, G2/M cell cycle arrest, and Bcl-2 phosphorylation in tumor cell lines. J Agric Food Chem 50: 677-684, 2002.
27. Piela-Smith TH and Liu X: Feverfew extracts and the sesquiterpene lactone parthenolide inhibit intercellular adhesion molecule-1 expression in human synovial fibroblasts. Cell Immunol 209: 89-96, 2001.
28. Jakobsen CM, Denmeade SR, Isaacs JT, Gady A, Olsen CE and Christensen SB: Design, synthesis, and pharmacological evaluation of thapsigargin analogues for targeting apoptosis to prostatic cancer cells. J Med Chem 44: 4696-4703, 2001.
29. Tombal B, Weeraratna AT, Denmeade SR and Isaacs JT: Thapsigargin induces a calmodulin/calcineurin-dependent apoptotic cascade responsible for the death of prostatic cancer cells. Prostate 43: 303-317, 2000.